Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 1.
doi: 10.1038/s41586-025-09588-6. Online ahead of print.

Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis

Affiliations

Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis

Tanner Michaelis et al. Nature. .

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by a progressive loss of motor neurons. Neuroinflammation is apparent in affected tissues, including increased T cell infiltration and activation of microglia, particularly in the spinal cord1,2. Autoimmune responses are thought to have a key role in ALS pathology, and it is hypothesized that T cells contribute to the rapid loss of neurons during disease progression3,4. However, until now there has been no reported target for such an autoimmune response. Here we show that ALS is associated with recognition of the C9orf72 antigen, and we map the specific epitopes that are recognized. We show that these responses are mediated by CD4+ T cells that preferentially release IL-5 and IL-10, and that IL-10-mediated T cell responses are significantly greater in donors who have a longer predicted survival time. Our results reinforce the previous hypothesis that neuroinflammation has an important role in ALS disease progression, possibly because of a disrupted balance of inflammatory and counter-inflammatory T cell responses4. These findings highlight the potential of therapeutic strategies aimed at enhancing regulatory T cells5, and identify a key target for antigen-specific T cell responses that could enable precision therapeutics in ALS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors have declared that no competing interests exist.

References

    1. Kawamata, T., Akiyama, H., Yamada, T. & McGeer, P. L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140, 691–707 (1992). - PubMed - PMC
    1. Engelhardt, J. I., Tajti, J. & Appel, S. H. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol. 50, 30–36 (1993). - PubMed - DOI
    1. Rodrigues Lima-Junior, J., Sulzer, D., Lindestam Arlehamn, C. S. & Sette, A. The role of immune-mediated alterations and disorders in ALS disease. Hum. Immunol. 82, 155–161 (2021). - PubMed - DOI
    1. Appel, S. H., Beers, D. R. & Zhao, W. Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation-mediated neurodegeneration. Curr. Opin. Neurol. 34, 765–772 (2021). - PubMed - DOI
    1. Thonhoff, J. R. et al. Combined regulatory T-lymphocyte and IL-2 treatment Is safe, tolerable, and biologically active for 1 year in persons with amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 9, e200019 (2022). - PubMed - PMC - DOI

LinkOut - more resources